Fremanezumab

瑞玛奈珠单抗

Report date: 2026/04/30 20:00:20

Base Information

Drug NameFremanezumab
Drug Alias NameFremanezumab-vfrmAjovyTEV-48125PF-4427429PF-04427429 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionCalcitonin gene-related peptide antagonists
TargetsCalcitonin gene-related peptide
Therapy Area/IndicationsPainCystitis, InterstitialPost-Traumatic Headache +[6] 
Global Approved IndicationsMigraine Disorders
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2018/09/14
Country/TerritoryCzechiaBelgiumCanada +[21] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaNDA/BLA
Originator CompaniesTevaPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesTeva Branded Pharmaceutical Products R&D LLCTeva GmbhVetter Pharma-Fertigung Gmbh & Co Kg +[7] 
Inactive CompaniesPfizer IncOtsuka Pharmaceutical Co Ltd
Active IndicationsMigraine Disorders
Inactive IndicationsPainCystitis, InterstitialPost-Traumatic Headache +[5] 

Other Information

ATC CodeN02CD03
Related LinksN/A